How did MDXG's recent EPS compare to expectations?
The most recent EPS for MiMedx Group Inc is $-0.07, beating expectations of $-0.02.
How did MiMedx Group Inc MDXG's revenue perform in the last quarter?
MiMedx Group Inc revenue for the last quarter is $-0.07
What is the revenue estimate for MiMedx Group Inc?
According to 8 of Wall street analyst, the revenue estimate of MiMedx Group Inc range from $75.7M to $66.05M
What's the earning quality score for MiMedx Group Inc?
MiMedx Group Inc has a earning quality score of A-/60.72686. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does MiMedx Group Inc report earnings?
MiMedx Group Inc next earnings report is expected in 2026-07-28
What are MiMedx Group Inc's expected earnings?
MiMedx Group Inc expected earnings is $66.32M, according to wall-street analysts.
Did MiMedx Group Inc beat earnings expectations?
MiMedx Group Inc recent earnings of $58.99M does not beat expectations.
Key Stats
Prev.Close
$4.36
Open
$4.36
Day's Range
$4.21 - $4.45
52 week range
$3.03 - $7.99
Volume
1.4M
Avg.Volume
1.4M
Dividend yield
--
EPS (TTM)
0.20
Market Cap
$630.0M
What is MDXG?
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.